Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes

Temple University, Philadelphia, Pennsylvania, USA.
Diabetes care (Impact Factor: 8.57). 03/2009; 32(6):1017-9. DOI: 10.2337/dc08-1776
Source: PubMed

ABSTRACT To assess the risk factors for the presence and severity of obstructive sleep apnea (OSA) among obese patients with type 2 diabetes.
Unattended polysomnography was performed in 306 participants.
Over 86% of participants had OSA with an apnea-hypopnea index (AHI) >or=5 events/h. The mean AHI was 20.5 +/- 16.8 events/h. A total of 30.5% of the participants had moderate OSA (15 <or= AHI <30), and 22.6% had severe OSA (AHI >or=30). Waist circumference (odds ratio 1.1; 95% CI 1.0-1.1; P = 0.03) was significantly related to the presence of OSA. Severe OSA was most likely in individuals with a higher BMI (odds ratio 1.1; 95% CI 1.0-1.2; P = 0.03).
Physicians should be particularly cognizant of the likelihood of OSA in obese patients with type 2 diabetes, especially among individuals with higher waist circumference and BMI.

Download full-text


Available from: Xavier Pi-Sunyer, Jul 01, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnea causes intermittent hypoxia (IH) and is associated with insulin resistance and type 2 diabetes. IH increases plasma catecholamine levels, which may increase insulin resistance and suppress insulin secretion. The objective of this study was to determine if adrenal medullectomy (MED) prevents metabolic dysfunction in IH. MED or sham surgery was performed in 60 male C57BL/6J mice, which were then exposed to IH or control conditions (intermittent air) for 6 weeks. IH increased plasma epinephrine and norepinephrine levels, increased fasting blood glucose and lowered basal and glucose-stimulated insulin secretion. MED decreased baseline epinephrine and prevented the IH induced increase in epinephrine, whereas the norepinephrine response remained intact. MED improved glucose tolerance in mice exposed to IH, attenuated the impairment in basal and glucose-stimulated insulin secretion, but did not prevent IH-induced fasting hyperglycemia or insulin resistance. We conclude that the epinephrine release from the adrenal medulla during IH suppresses insulin secretion causing hyperglycemia.
    Respiratory Physiology & Neurobiology 08/2014; 203. DOI:10.1016/j.resp.2014.08.018 · 1.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A major concern with sleep-disordered breathing conditions, which include obstructive sleep apnea (OSA), central apnea, and congenital central hypoventilation syndrome (CCHS), is the high incidence of accompanying autonomic dysfunction and metabolic disorders. Patients with OSA show exaggerated sympathetic tone, leading to hypertension, cardiac arrhythmia, profuse sweating, impaired cerebral perfusion, and stroke. In addition, OSA appears in 86% of obese Type II diabetic patients, suggesting common deleterious processes. Autonomic deficiencies also appear in CCHS patients, who are often hypoglycemic. The impaired autonomic control may stem from injury to central sympathetic and parasympathetic regulatory areas resulting from apnea-related inflammation, hypoxia, or perfusion-related consequences in OSA, and genetic mutation repercussions in CCHS. Disturbed sleep organization from apnea arousals may also disrupt hormonal release. Brain areas affected in both OSA and CCHS include cortical and limbic regions that influence hypothalamic-regulated sympathetic control and hormone release, essential for glycemic regulation, as well as parasympathetic nuclei influencing the pancreas and other viscera, and raphé serotonergic sites, important for thermal and vascular regulation. Brain injury and altered functional responses appear in OSA and CCHS, assessed with magnetic resonance imaging techniques, in areas which show regional gray matter loss, alterations of free water within tissue, loss of axonal integrity, and disruption of functional responses to autonomic and ventilatory challenges. Evaluation of neural injury and distortion in functional signals to autonomic challenges in localized brain areas can provide insights into common pathological mechanisms for dysregulation of hormonal release and autonomic processes in sleep-disordered breathing and metabolic disorders.
    The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology 09/2012; 295(9):1385-95. DOI:10.1002/ar.22514 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnea is characterized by repeated episodes of upper airway collapse during sleep, leading to apneic and hypopneic episodes, oxygen desaturation, and sleep fragmentation. This condition is closely associated with features of “metabolic syndrome” as well as overt diabetes. Although the association of metabolic abnormalities clearly portend increased cardiovascular risk, it remains unclear to what extent obesity confounds these associations. Attempts to demonstrate a causal relationship between obstructive sleep apnea and insulin resistance have yielded conflicting results. Although several recent studies have demonstrated a relationship between obstructive sleep apnea and diabetes mellitus independent of obesity, there are currently limited data demonstrating a strong causative link. The currently proposed pathophysiology involves intermittent hypoxia, sleep fragmentation, sympathetic activation, oxidative stress, an increase in proinflammatory adipocytokines, and hyperleptinemia and leptin resistance. Although continuous positive airway pressure has shown promise in treating obstructive sleep apnea and its associated metabolic derangements, two recent large, randomized controlled trials have redoubled the emphasis on weight loss in treating the triad of metabolic syndrome, diabetes, and obstructive sleep apnea. Weight loss and aggressive lifestyle intervention remain a common treatment modality for all of these conditions and should always be considered first-line treatment for this clinical construct. KeywordsObstructive sleep apnea-Metabolic syndrome-Insulin resistance-Diabetes mellitus
    Current Cardiovascular Risk Reports 03/2010; 4(2):165-173. DOI:10.1007/s12170-010-0083-y